EGFR and non-small cell lung carcinoma: A phase I clinical trial (NCT01869166) of EGFR CAR-T therapy in 11 patients with EGFR+ refractory/relapsed NSCLC demonstrated partial responses in 2 patients and stable disease in 5, with a duration of 2 to 8 months, without significant toxicity [55].